Now more than ever, businesses are expected to lead in the present and drive progress for the future. For more than 130 years, Johnson & Johnson has aimed to create a healthier world. Today, as the world’s largest and most broadly based healthcare company, we have a unique ability to apply our expertise and partnering power to help solve some of the most challenging global health issues. Our environmental, social and governance (ESG) strategy is designed to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.
In all we do, we are guided by the values outlined in Our Credo. Created more than 75 years ago, Our Credo declares our responsibility to our key stakeholders: our patients, healthcare providers, employees, communities and shareholders.
Our Credo values drive us to achieve Our Purpose—changing the trajectory of health for humanity—and ground our business strategy. This reflects our long-held belief that creating societal value is inextricably linked with generating long-term business value.
Through our Enterprise principles and our global growth drivers we enable our continued growth and performance against our ESG strategy.
Enterprise principles
- remain broadly based in healthcare
- use our reach and size for good
- lead with agility and urgency
- invest for enduring impact
Global growth drivers
- create life-enhancing innovation
- deliver excellence in execution
- generate shared value through partnerships
- empower and inspire our employees
Our ESG Strategy
We deliver enduring impact and create long-term value for our business and society by implementing our ESG ESG Environmental, social and governance strategy.
Our Credo
Our Purpose
and responsible business practices
across the value chain.
As a purpose-driven company, how we deliver enduring impact is embedded in our business strategy through the execution of our ESG strategy, which frames our ambitions, informs our operations and creates accountability for our vision of the future.
At the most senior level, our Board of Directors oversees the Executive Committee's implementation of our ESG strategy to promote responsible business practices through a culture of integrity and accountable leadership across our Company.
We focus our efforts on the areas where we are uniquely positioned to achieve the greatest impact—championing global health equity, empowering our employees and advancing environmental health. Leading with accountability and innovation is foundational to these efforts and essential to achieving Our Purpose, creating a virtuous circle that creates economic, environmental and social value for all those we serve.
We create long-term value by helping to achieve better health outcomes for patients and healthcare providers, foster rewarding opportunities for our employees and suppliers; protect and strengthen the communities in which we live and work; and provide profitable, sustainable growth for investors.
For more information, see our ESG Strategy and our ESG Resources.
Health for Humanity 2025 Goals
Measuring our ESG progress: We have a long history of setting and making progress toward our Health for Humanity Goals. In 2021, we launched our ambitious set of Health for Humanity 2025 Goals. Our Health for Humanity 2025 Goals align to our ESG ESG Environmental, social and governance focus areas and foundation of accountability and innovation, and are how we hold ourselves publicly accountable in creating a more sustainable society. We measure and publicly track performance against our Goals, with progress assured by a third party.
Through our Health for Humanity Goals, we support 11 of the 17 UN Sustainable Development Goals (SDGs), an ambitious global agenda to achieve a sustainable future by 2030. We are dedicating our expertise, ideas and ingenuity to catalyze efforts toward achieving those SDGs where the Company’s unique constellation of strengths can help create scalable societal impact.
Health for Humanity 2025 Goals Scorecard At-A-Glance
| Global Health Equity | placeholder | placeholder | placeholder |
|---|---|---|---|
|
|||
| Goal | Key Performance Indicator | Target | 2021 Status |
| Global Access Plans | % of identified assets from Johnson & Johnson Global Public Health and Janssen Infectious Diseases & Vaccines R&D pipeline with global access plans in place by 2025 | 100% | 
|
| Access to HIV Treatment | LAI LAI Long-acting injectable Access Program in place in two RLS RLS Resource-limited settings countries | Two countries |
|
| Access to Tuberculosis Treatment | # of cumulative patients receiving access to bedaquiline molecule (branded and generic) globally from 2021 through to end of 2025 | 700,000 |
|
| Developing Tuberculosis (TB) Treatment | Stringent regulatory authority approval of a new TB drug/regimen that reduces treatment length and is at least as effective and safe as the current recommended treatment by 2030 | New TB drug/regimen |
|
| Access to Schizophrenia Treatment | Complete a clinical study to demonstrate the health, economic and social value of using paliperidone palmitate LAI to treat schizophrenia in Rwanda by 2024 | Complete clinical study |
|
| Support Frontline Health Workers | # of nurses, midwives and community health workers reached globally | 1,000,000 |
|
| Reduce Burden of Obstetric Fistula | # of fistula repair surgeries (based on surgeries reported or product donated) | 10,000 |
|
| Preventive Viral Vaccine Capabilities | Create playbook including Documented Organizational Readiness for Pandemic Preparedness based on the demonstrated accelerated process for emergency use licensure submission of our COVID-19 vaccine | Create playbook |
|
| Vaccination Monitoring Platform | Adoption of endorsed platform by at least two countries by 2025 | Two countries |
|
| Healthcare for Women | Three best-practice healthcare for women insights published | Three |
|
Our Employees
| Our Employees | placeholder | placeholder | placeholder |
|---|---|---|---|
|
|||
| Goal | Key Performance Indicator | Target | 2021 Status |
| Women in Management | % of women in management positions | 50% |
|
| Ethnic/Racial Diversity in Management | % of ethnic/racial diversity in management positions in the U.S. | 35% |
|
| Black/African Americans in Management | % of Black and African American employees in management positions in the U.S. | 50% growth from 2020 |
|
| Healthiest Workforce Score | % of Johnson & Johnson leaders and managers achieving ≥80% annual Healthiest Workforce Score | 80% of leaders and their managers |
|
| Women in STEM²D | # of girls who have participated in virtual or in-person activities led by employees in partnership with nonprofit partners | 2,000,000 |
|
Environmental Health
| Environmental Health | placeholder | placeholder | placeholder |
|---|---|---|---|
|
|||
| Goal | Key Performance Indicator | Target | 2021 Status |
| Renewable Electricity | % renewable electricity globally | 100% |
|
| Carbon Neutrality for Our Operations | % absolute reduction in greenhouse gas (GHG) emissions – Scope 1 + 2 + carbon credits vs. 2016 baseline | 100% |
|
| Scope 3 Emissions Reductions | % absolute reduction in greenhouse gas (GHG) emissions – Scope 3 (upstream) vs. 2016 baseline | 20% |
|
Accountability & Innovation
| Accountability & Innovation | placeholder | placeholder | placeholder |
|---|---|---|---|
|
|||
| Goal | Key Performance Indicator | Target | 2021 Status |
| Supplier Sustainability Program | All suppliers included in one of the three Tiers | All suppliers |
|
| Global Supplier Diversity and Inclusion | Spend with Tier 1 small and diverse suppliers, social enterprise and Tier 2 supplier spend | $4.5 billion | 
|
| Partnerships for Good | # of supplier partnerships | 10 |
|
